Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: opalapril who wrote (9626)	4/14/1999 2:08:00 PM
From: aknahow	Respond to of 17367

It is possible GNE failed to say that they had an agreement in principal pending resolution of details. But even so I still think XOMA could have and should have said the same thing with perhaps a mention of the areas, not the specifics, where agreement was still being sought. I do hope XOMA will make some sort of P.R. release following or in conjunction with Castello's presentation tomorrow. I remain convinced they are near termination of the meningococcemia trial. They would not have said so if this was not true but logic also leads one to think that with 381 patients closure must be near. What I fear is that even if the trial ends with success XOMA will somehow, perhaps out of fear of law suits, be unable to generate any excitement for this event. BTW Martin is on vacation. IMO Doyle is very competent. I do not think the problem with GNE nor failing to release information after corporate presentations is specifically an IR problem. Think it's upper management.

To: opalapril who wrote (9626)	4/14/1999 3:50:00 PM
From: aknahow	Respond to of 17367

"Xoma Ltd. (XOMA) — Beginning to release late-stage data from multiple trials of Neuprex, starting with preliminary Phase III data in children with severe meningococcemia, as well as Phase II results for hu1124 humanized MAb in plaque psoriasis, partnered with Genentech Inc. (GNE)." IMO the wording comes from XOMA rather than from the conference organizers that have no idea of what the company wants to say. If XOMA said this as a header to its' presentation I have to believe they intend to say something tomorrow. My concern remains that even if they do, they might not tell us anything.